摘要
肝细胞癌(HCC)是我国发病率和死亡率均较高的恶性肿瘤,其中晚期阶段是当前治疗中的难点。免疫检查点抑制剂(ICI)作为新兴治疗方案在临床中虽显示出一定的效果,但存在总体应答率低和免疫相关不良事件发生较多等问题。中医药在中晚期HCC治疗中具有独特优势。本文通过系统回顾近年相关研究发现,中医药联合ICI可通过多成分、多靶点、多途径协同机制,在中晚期HCC治疗中发挥控制疾病进展、延长患者生存时间及减少免疫相关不良事件等作用,其潜在机制可能涉及直接抑制肿瘤细胞、调节机体免疫系统及肠道菌群等多个方面。
Hepatocellular carcinoma(HCC)is a malignant tumor with high incidence and mortality rates in China,and advanced HCC is a difficult issue in current treatment.Immune checkpoint inhibitor(ICI),as an emerging treatment regimen,has shown a certain effect in clinical practice,but there are still problems such as low overall response rate and a high incidence rate of immunerelated adverse events(irAEs).Traditional Chinese medicine exhibits unique advantages in the treatment of advanced HCC.Through a retrospective analysis of related studies in recent years,this article shows that traditional Chinese medicine combined with ICI can control disease progression,prolong survival time,and reduce irAEs in the treatment of advanced HCC through the synergistic effect between multiple components,targets,and pathways.The potential mechanism of this treatment modality may involve various aspects such as the direct inhibition of tumor cells and the regulation of immune system and intestinal flora.
作者
李永琪
李妍秋
孙丽娜
王超冉
冯颖
王宪波
LI Yongqi;LI Yanqiu;SUN Lina;WANG Chaoran;FENG Ying;WANG Xianbo(Center of Integrative Medicine,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China)
出处
《临床肝胆病杂志》
北大核心
2025年第11期2397-2402,共6页
Journal of Clinical Hepatology
基金
国家自然科学基金(82474419)
国家中医药管理局高水平中医药重点学科建设项目(zyyzdxk-2023005)
首都卫生发展科研专项(2024-1-2173)。
关键词
癌
肝细胞
免疫检查点抑制剂
中医药疗法
Carcinoma,Hepatocellular
Immune Checkpoint Inhibitors
Traditional Chinese Medicine Therapy
